Join Bharat Equity Telegram Channel for updated India results, analysis and News
[s2If !current_user_can(access_s2member_level1)][lwa][/s2If] [s2If current_user_can(access_s2member_level1)]
Our Rating:
Mehabe score: 3
G Factor: 4
Piotski Score: 8
The stock has a rating . The mehabe team score is reflective of its fundamental and technical merits. A rating above 8 is considered good buy. The stock has a G-Factor of 4 and Piotski score of 8.
Description
Marksans Pharma is engaged in the Business of Formulation of pharmaceutical products.Site: MARKSANSMain Symbol: MARKSANS
Price Chart
| Market Cap: | Rs 2,757 cr | Price: | 67.4 | Trading pe: | 11.0x |
| Book-value: | 21.7/share | Div yield: | 0.37 % | Earning yield: | 12.22% |
| Face-value: | 1.00/share | 52week high: | 97.60 | 52week low: | 48.00 |
Technical Analysis
- Stock trades at 67.4, below its 50dma 73.22 and below its 200dma 67.97. The stock remains bearish on technicals
- The 52 week high is at 97.60 and the 52week low is at 48.00
Price Chart
P/E Chart
Sales and Margin
Strengths
– is almost debt free.
– has delivered good profit growth of 24.76% CAGR over last 5 years
Weakness
– The company has delivered a poor sales growth of 9.03% over past five years.
Competition
– The industry trades at a mean P/E of 21.7x. Divi’s Lab. trades at the industry’s max P/E of 61.53x. MARKSANS trades at a P/E of 11.0x
– Industry’s mean G-Factor is 3.2 while the mean Piotski score is 8.0. MARKSANS has a G-Factor of 4 and Piotski scoreof 8.
– Average 1 month return for industry is -3.5%. The max 1- month return was given by Hikal: a return of 0.88 %
Quarterly Results
- Sales for period ended Jun 2021 is Rs 349.0 cr compared to Rs 331.0 cr for period ended Jun 2020, a rise of 5.4%
- Operating Profits reported at Rs 77.0 cr for period ended Jun 2021 vis-vis 70.0 for period ended Jun 2020 .
- Operating Margins expanded 91.5 bps for period ended Jun 2021 vis-vis Jun 2020 .
- The EPS for Jun 2021 was Rs 1.53 compared to Rs 1.94 for previous quarter ended Mar 2021 and Rs 1.21 for Jun 2020
Profit & Loss Statement
Profit&Loss Comments
- Company reported sales of Rs 1394.0 cr for period ended TTM vis-vis sales of Rs 1376.0 cr for the period ended Mar 2021, a growth of 1.3%. The 3 year sales cagr stood at 11.7%.
- Net Profit reported at Rs 252.0 cr for period ended TTM vis-vis sales of Rs 239.0 cr for the period ended Mar 2021, rising 5.2%.
- Company recorded a healthy Net Profit CAGR of 49.1% over the last 3 years
Balance Sheet Statement
Cash Flow Statement
Cash Flow comments
- CashFlow from operating activities was positive.
Sales Growth
Profit Growth Statement
Profit Growth Statement
Stock Price CAGR
Return of Equity
General Comments
– The company has improved its Return on Equity (RoE) metric. The RoE on Last Year basis was 31.0% compared to 23.0% over the last 3 Years.
– The stock has given a return of 37% on a 1 Year basis vis-vis a return of 25% over the last 3 Years.
– The compounded sales growth on a TTM bassis is 15% vis-vis a compounded sales growth of 15% over the last 3 Years.
– The compounded profit growth on a TTM basis is 71% vis-vis a compounded profit growth of 93% over the last 3 Years.
Ratios
Shareholding Pattern
– FII shareholding has remained largely constant. The Sep 2021 fii holding stood at 2.64% vis-vis 3.14% for Jun 2021
– Public shareholding has remained largely constant. The Sep 2021 public holding stood at 48.58% vis-vis 48.05% for Jun 2021
Conclusion
– is almost debt free.
– has delivered good profit growth of 24.76% CAGR over last 5 years – The company has delivered a poor sales growth of 9.03% over past five years.
[/s2If]
Join Bharat Equity Telegram Channel for updated India results, analysis and News